MER-BCG (NSC-143769): immunogenicity and toxicity of single and repeated intradermal injections in dogs.
Intradermal injections of MER-BCG 0.1 mg or 0.2 mg at each of 10 multiple sites, led to local granuloma formation. The nodules reached approximately 10 mm in diameter, ulcerated and were accompanied by granulomatous changes in the regional lymph nodes. Six or twelve successive treatments (each including 10 injections) at 4 week intervals produced the same histopathological lesions but no changes in hematological and blood chemical parameters or general morphology and no changes in general condition with exception of occasional weight loss in a few animals. Injection with 0.01 or 0.001 mg/site produced similar, though less severe, skin lesions but no changes in the draining lymph nodes. The immunogenicity of MER-BCG was characterized by granuloma formation, a positive skin response to old tuberculin, and a positive lymphocyte transformation to PPD tuberculin, thus indicating stimulation of cell-mediated immune responses. However, there was a decreased responsiveness to PHA and PPD with continuing treatment with MER-BCG. The decreased responsiveness and accumulation of numerous depots of antigen would suggest an "immunologic paralysis" contraindicating the administration of excessive amounts of MER-BCG during immunotherapy. A specific humoral response to the administration of MER-BCG was not detected, but an MER-BCG dose independent decrease in albumin associated with a non-specific, dose related elevation in serum IgG was observed.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001500:BCG Vaccine / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D004285:Dogs; D005260:Female; D007111:Immunity, Cellular / Q000187:drug effects; D007271:Injections, Intradermal; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; C011499:methanol extraction residue (MER) tubercle bacillus fraction